1. Scrip
  2. >>Conferences
  3. >>ASCO

ASCO: AstraZeneca Touts LAURA’s Large PFS Benefit In EGFR-Mutant NSCLC

 
• By Alaric DeArment

While the study allowed a crossover, and the overall survival benefit did not reach statistical significance, the drug maker sees the PFS benefit from Tagrisso as likely to drive uptake.

• Source: Scrip

AstraZeneca PLC’s Tagrisso (osimertinib) is likely to become the standard of care for patients with unresectable locally advanced stage III EGFR-mutant non-small cell lung cancer (NSCLC) who have undergone chemoradiotherapy, based on Phase III data presented at the American Society of Clinical Oncology annual meeting showing an overwhelming benefit on the primary endpoint of progression-free survival (PFS).

The drug maker unveiled data from the Phase III LAURA trial of Tagrisso in the ASCO plenary session on 2 June, showing an improvement in PFS in a population that lacks approved therapies

Key Takeaways

  • AstraZeneca presented results from the Phase III LAURA study of Tagrisso in unresectable locally advanced stage III NSCLC in a plenary at ASCO.

  • The results showed a more than 33-month benefit in progression-free survival, which oncologists called “practice changing

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

 
• By Alaric DeArment

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

 
• By Alaric DeArment

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

ASCO 2024 Wrap-Up Podcast

 
• By Alaric DeArment

Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.   

China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights

 
• By Brian Yang and Dexter Jie Yan

US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.

More from Conferences

Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain

 
• By Jessica Merrill

CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.

Reflections From Biotech Leader John Maraganore

 
• By Jessica Merrill

The founder and director of City Therapeutics and founding CEO of Alnylam discussed pressing issues facing the biotech sector in a fireside chat at the recent BIO CEO & Investor Conference.

M&A Takeoff May Be Delayed, Experts Predict

 
• By Jessica Merrill

All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.